


## Resiquimod [144875-48-9]

#Cat: NB-64-37515-1mg	Size: 1mg
#Cat: NB-64-37515-5mg	Size: 5mg
#Cat: NB-64-37515-1ml	Size: 1ml
#Cat: NB-64-37515-10mg	Size: 10mg
#Cat: NB-64-37515-25mg	Size: 25mg
#Cat: NB-64-37515-50mg	Size: 50mg
#Cat: NB-64-37515-100mg	Size: 100mg
#Cat: NB-64-37515-200mg	Size: 200mg
#Cat: NB-64-37515-500mg	Size: 500mg

### Chemical Properties

Cas No:	144875-48-9
Formula:	C <sub>17</sub> H <sub>22</sub> N <sub>4</sub> O <sub>2</sub>
Molecular weight:	314.38
Appearance:	no data available
Storage:	store at low temperature Powder: -20°C for 3 years   In solvent: -80°C for 1 year



### Biological Description

<b>Description</b>	Resiquimod (R848) is a Toll-like receptor 7/8 (TLR7/TLR8) agonist that induces cytokine upregulation. Resiquimod is an immunomodulator with antitumor and antiviral activity.
<b>Targets(IC<sub>50</sub>)</b>	HCV Protease,TLR
<b>In vitro</b>	<p><b>Methods:</b> Golden pompholyte kidney lymphocytes HKL were treated with Resiquimod (0.175-32 µg/mL) for 12 h. Cell viability was measured by CCK8 assay.</p> <p><b>Results:</b> CCK8 assay showed that 0.25-32 µg/mL Resiquimod significantly promoted HKL proliferation. [1]</p> <p><b>Methods:</b> Peripheral blood mononuclear cells PBM were treated with Resiquimod (0.01-100 µM) for 1-14 h, and the expression levels of target proteins were detected by Western Blot.</p> <p><b>Results:</b> A dose of 1 µM was sufficient to alter the expression of FcγR, and higher doses did not result in greater changes. the increase in FcγRIIIa occurred at a late stage, while a small increase in the γ chain was seen at 3 h, but was higher at 14 h. However, the FcγRIIb protein decreases at 1 h, while the FcγRIIb transcript is maintained until 4 h.[2]</p>
<b>In vivo</b>	<p><b>Methods:</b> To detect anti-tumor activity in vivo, Resiquimod (2 mg/kg) and 4D5 antiHER2 antibody (20 mg/kg) were injected intraperitoneally three times per week for 13 days into Balb/cJ mice bearing CT26-HER2/neu tumors.</p> <p><b>Results:</b> After 13 days, the tumor growth rate of mice receiving Resiquimod plus antibody was significantly reduced. Statistical tests showed a synergistic effect of 4D5 and Resiquimod in reducing tumor growth rate. [2]</p>
<b>Kinase Assay</b>	For luciferase assay, FG-9307 cells are transfected with the firefly NF-κB-specific luciferase reporter vector pNFκB-Met-Luc2. Transfection efficiency is monitored by cotransfection with the pSEAP2 control vector, which constitutively expresses the human secreted enhanced alkaline phosphatase (SEAP). Then the cells are treated with Resiquimod (R848, 1?µg/mL), CQ (10?µM), CQ plus R848 or PBS and incubated at 22°C for 24?h. The culture medium of the transfectants is then analyzed for luciferase

	activity and SEAP activity using Luciferase Assay Kit and the Great EscAPE? SEAP Chemiluminescence Detection Kit, respectively. The assay is performed three times.
<b>Cell Research</b>	Resiquimod is dissolved in DMSO. For inhibition of lysosomal acidification, cells are incubated with 10 $\mu$ M CQ for 1h before Resiquimod (R848) treatment. After treatment, 20 $\mu$ L of 5mg/mL MTT is added to the plate. The plate is incubated at 22°C for 4h, and 200 $\mu$ L dimethyl sulfoxide is added to the plate to dissolve the reduced formazan. The plate is then read at 490nm with a microplate reader. To determine the effect of Myd88 inhibition on R848-induced cell proliferation, the Myd88 inhibitor Pepinh-MYD and the control peptide Pepinh-Control are added to PBL at the concentration of 50 $\mu$ M, and the plate is incubated at 22°C for 6h. After incubation, the cells are treated with R848 and subjected to MTT assay as above. To determine the effect of NF- $\kappa$ B inactivation on R848- induced cell proliferation, BAY-11-7082, an irreversible inhibitor of I $\kappa$ B- $\alpha$ phosphorylation, is added to the cells at the concentration of 1 $\mu$ M, and the plate is incubated at 22°C for 1h. After incubation, the cells are treated with R848 and subjected to MTT assay as earlier. All experiments are performed three times.
<b>Animal Research</b>	Animal Models: Wild-type mice, TLR7-deficient mice, and MyD88-deficient mice. Formulation: saline. Dosages: 50 nmol. Administration: i.p.

## Solubility Information

<b>Solubility</b>	H <sub>2</sub> O: 1 mg/mL (insoluble or slightly soluble), 10% DMSO+90% Saline: 0.1 mg/mL (0.32 mM), In vivo: Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. DMSO: 55 mg/mL (174.95 mM), Ethanol: 20 mg/mL (63.6 mM), ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
-------------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.1809 mL	15.9043 mL	31.8086 mL
5 mM	0.6362 mL	3.1809 mL	6.3617 mL
10 mM	0.3181 mL	1.5904 mL	3.1809 mL
50 mM	0.0636 mL	0.3181 mL	0.6362 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

## Reference

- Zhou Y, et al. R848 Is Involved in the Antibacterial Immune Response of Golden Pompano (*Trachinotus ovatus*) Through TLR7/8-MyD88-NF- $\kappa$ B-Signaling Pathway. *Front Immunol.* 2021 Jan 18;11:617522.
- Gao Y, Wang K, Wang P, et al A novel network pharmacology strategy to decode mechanism of Lang Chuang Wan in treating systemic lupus erythematosus. *Frontiers in Pharmacology.* 2020, 11.
- Li J X, Shu N, Zhang Y J, et al. Self-Assembled Nanoparticles from the Amphiphilic Prodrug of Resiquimod for Improved Cancer Immunotherapy. *ACS Applied Materials & Interfaces.* 2024
- Butchar JP, et al. Reciprocal regulation of activating and inhibitory Fc $\gamma$  receptors by TLR7/8 activation: implications for tumor immunotherapy. *Clin Cancer Res.* 2010 Apr 1;16(7):2065-75.
- Lee M, et al. *Arch Pharm Res.* 2014, 37(9), 1234-1240.
- Nadeem A, et al. *Int J Biochem Cell Biol.* 2016, 73, 53-62.
- Zhou ZX, et al. Immune effects of R848: evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF- $\kappa$ B-dependent signaling in the antiviral immunity of Japanese flounder (*Paralichthys olivaceus*). *Dev Comp Immunol.* 2015 Mar;49(1):113-20.
- Gao Y, Wang K, Wang P, et al. A novel network pharmacology strategy to decode mechanism of Lang Chuang Wan in treating systemic lupus erythematosus[J]. *Frontiers in Pharmacology.* 2020, 11.